ong-Term Safety Follow-Up Of Subjects Previously Enrolled In Rheumatoid Arthritis Studies Of CP-690,550
Phase 2
Completed
- Conditions
- Health Condition 1: null- Arthritis, Rheumatoid
- Registration Number
- CTRI/2009/091/000722
- Lead Sponsor
- Pfizer Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 300
Inclusion Criteria
Ages Eligible for Study:18 Years and older,
Genders Eligible for Study:Both,
Accepts Healthy Volunteers:No,
Sampling Method:Non-Probability Sample,
Study Population
Subjects who have received at least one dose of study drug and ceased participation in any Phase 2B or 3 randomized, controlled or open-label (qualifying) study of CP-690,550 for the treatment of RA, but are no longer receiving CP-690,550.
Criteria
Inclusion Criteria:
- Subjects who have completed all participation in any other Phase 2B or Phase 3 studies of CP-690,550 for rheumatoid arthritis.
Exclusion Criteria
Any subject who refuses consent.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method